186 related articles for article (PubMed ID: 36430649)
1. Akt-Activated Endothelium Increases Cancer Cell Proliferation and Resistance to Treatment in Ovarian Cancer Cell Organoids.
Hoarau-Véchot J; Blot-Dupin M; Pauly L; Touboul C; Rafii S; Rafii A; Pasquier J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430649
[TBL] [Abstract][Full Text] [Related]
2. Akt-activated endothelium promotes ovarian cancer proliferation through notch activation.
Hoarau-Véchot J; Touboul C; Halabi N; Blot-Dupin M; Lis R; Abi Khalil C; Rafii S; Rafii A; Pasquier J
J Transl Med; 2019 Jun; 17(1):194. PubMed ID: 31182109
[TBL] [Abstract][Full Text] [Related]
3. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.
Correa RJ; Peart T; Valdes YR; DiMattia GE; Shepherd TG
Carcinogenesis; 2012 Jan; 33(1):49-58. PubMed ID: 22045027
[TBL] [Abstract][Full Text] [Related]
4. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
Al Habyan S; Kalos C; Szymborski J; McCaffrey L
Oncogene; 2018 Sep; 37(37):5127-5135. PubMed ID: 29789717
[TBL] [Abstract][Full Text] [Related]
5. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
[TBL] [Abstract][Full Text] [Related]
6. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
7. Omentum-on-a-chip: A multicellular, vascularized microfluidic model of the human peritoneum for the study of ovarian cancer metastases.
Ibrahim LI; Hajal C; Offeddu GS; Gillrie MR; Kamm RD
Biomaterials; 2022 Sep; 288():121728. PubMed ID: 35995621
[TBL] [Abstract][Full Text] [Related]
8. BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation.
Peart TM; Correa RJ; Valdes YR; Dimattia GE; Shepherd TG
Clin Exp Metastasis; 2012 Apr; 29(4):293-313. PubMed ID: 22249415
[TBL] [Abstract][Full Text] [Related]
9. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
Tadić V; Zhang W; Brozovic A
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
11. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer.
Guerrouahen BS; Pasquier J; Kaoud NA; Maleki M; Beauchamp MC; Yasmeen A; Ghiabi P; Lis R; Vidal F; Saleh A; Gotlieb WH; Rafii S; Rafii A
Mol Cancer Ther; 2014 Dec; 13(12):3123-36. PubMed ID: 25319392
[TBL] [Abstract][Full Text] [Related]
12. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
14. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.
Rakina M; Kazakova A; Villert A; Kolomiets L; Larionova I
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682890
[TBL] [Abstract][Full Text] [Related]
15. Surgical peritoneal stress creates a pro-metastatic niche promoting resistance to apoptosis via IL-8.
Pasquier J; Vidal F; Hoarau-Véchot J; Bonneau C; Daraï E; Touboul C; Rafii A
J Transl Med; 2018 Oct; 16(1):271. PubMed ID: 30285881
[TBL] [Abstract][Full Text] [Related]
16. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model.
Touboul C; Lis R; Al Farsi H; Raynaud CM; Warfa M; Althawadi H; Mery E; Mirshahi M; Rafii A
J Transl Med; 2013 Jan; 11():28. PubMed ID: 23369187
[TBL] [Abstract][Full Text] [Related]
18. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
19. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
20. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.
Correa RJ; Komar M; Tong JG; Sivapragasam M; Rahman MM; McFadden G; Dimattia GE; Shepherd TG
Gynecol Oncol; 2012 May; 125(2):441-50. PubMed ID: 22306204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
